Literature DB >> 10070955

Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression.

C A Reis1, L David, P Correa, F Carneiro, C de Bolós, E Garcia, U Mandel, H Clausen, M Sobrinho-Simões.   

Abstract

Intestinal metaplasia is a well-established premalignant condition of the stomach that is characterized by mucin carbohydrate modifications defined by histochemical methods. The purpose of the present study was to see whether the expression of mucin core proteins was modified in the different types of intestinal metaplasia and to evaluate the putative usefulness of mucins as "molecular markers" in this setting. We used a panel of monoclonal antibodies with well-defined specificities to MUC1, MUC2, MUC5AC, and MUC6 to characterize the expression pattern of mucins. In contrast to normal gastric mucosa, the complete form or type I intestinal metaplasia (n = 20) displayed little or no expression of MUC1, MUC5AC, or MUC6 in the metaplastic cells and strong expression of the intestinal mucin MUC2 in the goblet cells of all cases. The incomplete forms of intestinal metaplasia, type II (n = 25) and type III (n = 16), expressed MUC1 and MUC5AC in every case, both in goblet and in columnar cells. MUC6 was also expressed in 16 cases of type II intestinal metaplasia and in 11 cases of type III intestinal metaplasia. The intestinal mucin MUC2 was expressed in every case of incomplete intestinal metaplasia, mostly in goblet cells. The mucin expression profile in the different types of intestinal metaplasia allows the identification of two patterns: one defined by decreased levels of expression of "gastric" mucins (MUC1, MUC5AC, and MUC6) and expression of MUC2 intestinal mucin, which corresponds to type I intestinal metaplasia, and the other defined by coexpression of "gastric mucins" (MUC1, MUC5AC, and MUC6) together with the MUC2 mucin, encompassing types II and III intestinal metaplasia. Our results challenge the classical sequential pathway of intestinal metaplasia (from type I to type III via a type II intermediate step).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10070955

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  106 in total

1.  Gastric MUC5AC and MUC6 are large oligomeric mucins that differ in size, glycosylation and tissue distribution.

Authors:  Henrik Nordman; Julia R Davies; Gert Lindell; Carme de Bolós; Francisco Real; Ingemar Carlstedt
Journal:  Biochem J       Date:  2002-05-15       Impact factor: 3.857

Review 2.  Mucins and mucosal protection in the gastrointestinal tract: new prospects for mucins in the pathology of gastrointestinal disease.

Authors:  A P Corfield; N Myerscough; R Longman; P Sylvester; S Arul; M Pignatelli
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

3.  Essential role of gastric gland mucin in preventing gastric cancer in mice.

Authors:  Fumitoshi Karasawa; Akira Shiota; Yukinobu Goso; Motohiro Kobayashi; Yoshiko Sato; Junya Masumoto; Maiko Fujiwara; Shuichi Yokosawa; Takashi Muraki; Shinichi Miyagawa; Masatsugu Ueda; Michiko N Fukuda; Minoru Fukuda; Kazuhiko Ishihara; Jun Nakayama
Journal:  J Clin Invest       Date:  2012-02-06       Impact factor: 14.808

Review 4.  Cdx genes, inflammation, and the pathogenesis of intestinal metaplasia.

Authors:  Douglas B Stairs; Jianping Kong; John P Lynch
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

Review 5.  Prognostic value of Muc5AC in gastric cancer: A meta-analysis.

Authors:  Chuan-Tao Zhang; Ke-Cheng He; Fei Pan; Yuan Li; Jiang Wu
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

6.  Amphiregulin-deficient mice develop spasmolytic polypeptide expressing metaplasia and intestinal metaplasia.

Authors:  Ki Taek Nam; Hyuk-Joon Lee; Hoyin Mok; Judith Romero-Gallo; James E Crowe; Richard M Peek; James R Goldenring
Journal:  Gastroenterology       Date:  2008-12-13       Impact factor: 22.682

Review 7.  Host response in tumor diagnosis and prognosis: importance of immunologists and pathologists alliance.

Authors:  Olivera J Finn
Journal:  Exp Mol Pathol       Date:  2012-10-23       Impact factor: 3.362

Review 8.  Carbohydrate-dependent defense mechanisms against Helicobacter pylori infection.

Authors:  Motohiro Kobayashi; Heeseob Lee; Jun Nakayama; Minoru Fukuda
Journal:  Curr Drug Metab       Date:  2009-01       Impact factor: 3.731

Review 9.  Current status of mucins in the diagnosis and therapy of cancer.

Authors:  Satyanarayana Rachagani; Maria P Torres; Nicolas Moniaux; Surinder K Batra
Journal:  Biofactors       Date:  2009 Nov-Dec       Impact factor: 6.113

10.  Expression of UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase-6 in gastric mucosa, intestinal metaplasia, and gastric carcinoma.

Authors:  Joana Gomes; Nuno T Marcos; Nora Berois; Eduardo Osinaga; Ana Magalhães; João Pinto-de-Sousa; Raquel Almeida; Fátima Gärtner; Celso A Reis
Journal:  J Histochem Cytochem       Date:  2008-10-14       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.